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Abstract
Background: Hepcidin is a 25-residue peptide hormone crucial to iron homeostasis. It is essential
to measure the concentration of hepcidin in cells, tissues and body fluids to understand its
mechanisms and roles in physiology and pathophysiology. With a mass of 2791 Da hepcidin is
readily detectable by mass spectrometry and LC-ESI, MALDI and SELDI have been used to estimate
systemic hepcidin concentrations by analysing serum or urine. However, peak heights in mass
spectra may not always reflect concentrations in samples due to competition during binding steps
and variations in ionisation efficiency. Thus the purpose of this study was to develop a robust assay
for measuring hepcidin using a stable isotope labelled hepcidin spiking approach in conjunction with
SELDI-TOF-MS.
Results: We synthesised and re-folded hepcidin labelled with 13C/15N phenylalanine at position 9
to generate an internal standard for mass spectrometry experiments. This labelled hepcidin is 10
Daltons heavier than the endogenous peptides and does not overlap with the isotopic envelope of
the endogenous hepcidin or other common peaks in human serum or urine mass spectra and can
be distinguished in low resolution mass spectrometers. We report the validation of adding labelled
hepcidin into serum followed by SELDI analysis to generate an improved assay for hepcidin.
Conclusion: We demonstrate that without utilising a spiking approach the hepcidin peak height
in SELDI spectra gives a good indication of hepcidin concentration. However, a stable isotope
labelled hepcidin spiking approach provides a more robust assay, measures the absolute
concentration of hepcidin and should facilitate inter-laboratory hepcidin comparisons.
Background
Hepcidin, a 25-residue peptide hormone, is a key regula-
tor of iron homeostasis [1-3]. It is produced by hepato-
cytes and to a lesser extent by macrophages, bacteria-
activated neutrophils and colorectal cancer cells [2-5]. The
major stimuli for hepcidin expression include iron excess,
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inflammation and infection. Hepcidin exerts its biological
effect at the level of cellular iron export by binding to and
causing the internalisation and degradation of ferroportin
[6]. Thus in macrophages; the major cell type responsible
for iron recycling, the iron becomes trapped resulting in
an anaemia which in the context of inflammation and
infection is characterised as the anaemia of chronic dis-
ease [7].
There has been intense research into how hepcidin is reg-
ulated and its role in pathologies including haematologi-
cal disorders, liver disease and carcinogenesis [1,5,8]. The
method most commonly employed for measuring hepci-
din in serum and urine is surface enhanced laser desorp-
tion/ionisation time-of-flight mass spectrometry (SELDI)
[5,9-12]. SELDI offers facile high-throughput sample
preparation via on-chip retentate chromatography with
hepcidin binding to NP20, CM10 and IMAC surfaces
(normal-phase silica, cation exchange or immobilised
metal ion chromatography respectively). It is assumed the
height of the SELDI peak at m/z 2791 is related to hepci-
din concentration. However, although Tomosugi et al
report a linear relationship between SELDI peak height
and hepcidin concentration under ideal conditions [12]
and Bozzini et al demonstrate a correlation between
SELDI peak height and a dot-blot immunoassay [9], this
may not be a valid assumption when comparing samples
with variable proteomic backgrounds or using different
instruments. Doubts have been raised about the reproduc-
ibility of SELDI data [13-15]. Recently Swinkels and cow-
orkers [16,17] have used a truncated version of hepcidin
(hepcidin-24) as an internal standard. Most recently,
Ganz et al and Kobold et al have reported ELISA and LC-
ESI-MS with a stable isotope labelled standard to quanti-
tate hepcidin [18,19]. We now report the development of
a simple alternative method to assay hepcidin in human
serum combining the use of stable isotope labelled hepci-
din and SELDI-TOF-MS.
Methods
Hepcidin synthesis and folding
Human hepcidin was synthesised with or without 13C/15N
phenylalanine at position 9 (AltaBioscience, University of
Birmingham). This was dissolved at 0.1 mg/ml in 6 M
urea, 30 mM MOPS (pH 7.0) and incubated overnight at
room temperature with stirring. The folded hepcidin was
purified by C18 RP-HPLC in 0.1% TFA/acetonitrile. Hep-
cidin concentrations were determined by BCA assay cali-
brated with bovine serum albumin (Pierce).
Sample collection
Serum was collected from women attending routine
breast clinics at Russell's Hall Hospital, Dudley, UK
between 2005 and 2007 (LREC Ref 05/Q2709/48). All
subjects gave informed consent prior to venipuncture.
Venous blood was taken into serum collection tubes and
allowed to clot at room temperature for 1–2 hours. Sam-
ples were then centrifuged for 10 min at 3000 g and the
supernatant stored in aliquots at -80°C. The urine sample
used in the experiment of Figure 7 was selected on the
basis of hepcidin peak height from a previously analysed
set of urine samples [20].
SELDI
Sera were analysed on Cu2+-loaded IMAC30 ProteinChips
using a PBS IIc time-of-flight mass spectrometer (BioRad).
Sera were diluted 5-fold in 8 M urea, 1% CHAPS in bind-
ing buffer (0.5 M NaCl, 0.1 M sodium phosphate, pH 7.0)
followed by a further 10-fold dilution in binding buffer
and 100 μl applied to the chips. Following 30 minutes
binding the chips were washed with binding buffer, rinsed
with water, dried and 2 × 1 μl of 50% saturated sinapinic
acid in 50% acetonitrile/0.5% TFA added. Spectra were
collected over m/z 0–20,000 focussed at m/z 2800 using
a laser power of 165. Following mass calibration, total ion
current normalisation and baseline subtraction the hepci-
din peaks were manually picked and intensities (peak
heights) extracted using ProteinChip software.
Immunofluoresence
THP-1 cells were cultured in RPMI 1640 media containing
10% FCS, 2 mM L-glutamine, 1% penicillin/streptomy-
cin. To promote differentiation/activation cells were incu-
bated with 16 nM phorbol-12-myristate-13-acetate for 48
hours. Cells were then treated for 24 hrs with/without 0.5
μM folded or reduced labelled hepcidin (reduced with 2
mM tris(2-carboxyethyl)phosphinehydrochloride). Cells
were then fixed, blocked and incubated for 1 hr with an
anti-ferroportin rabbit polyclonal (1:100, clone 3566, this
antibody was raised against the oligopeptide CGKQLTSP-
KDTEPKPLEGTH corresponding to amino acids 247–264
of murine ferroportin as previously described [21]). Cells
were then labelled with FITC goat anti-rabbit (Jackson
Immunoresearch, 1:500), washed and visualised.
NMR spectroscopy
Spectra were acquired at 25°C on a Varian INOVA-800
spectrometer equipped with a cryoprobe as previously
reported [22]. Briefly, hepcidin (0.5 mg/ml) was prepared
in 50 mM phosphate buffer (pH 4.0) containing 120 mM
KCl in 90% H2O/10% D2O and 1H-1H through space cor-
relations obtained using standard homonuclear 2D
NOESY experiments with a 150-ms mixing time.
Statistics and analysis of reproducibility
Statistical significance was calculated using an unpaired
two tailed Student's t test. Trend lines were fitted using
standard least squares linear regression. Reproducibility
was estimated by analysing 2 serum samples spiked with
200 ng hepcidin/ml in quadruplicate on ProteinChipProteome Science 2008, 6:28 http://www.proteomesci.com/content/6/1/28
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arrays on 5 successive days. The intra-assay coefficients of
variation (CV (mean/standard deviation)) were calculated
from the 4 replicates of each sample on each ProteinChip
array and the inter-assay CVs by comparing across days.
Results
Hepcidin Folding
During folding 4 disulphide bridges form with the loss of
8 hydrogen atoms resulting in an 8 Da decrease in molec-
ular weight. We used ESI-FTICR mass spectrometry to
detect this mass change. The 3+ ions of the folded and
reduced forms of unlabelled and labelled hepcidin are
shown in Figure 1. The measured masses of the folded and
reduced unlabelled hepcidin, 2787.033 and 2795.106 Da,
agree with predicted values (2787.025 and 2795.088
respectively). The measured masses of the folded and
reduced labelled hepcidin are 2797.053 and 2805.134 Da
(predicted values 2797.053 and 2805.116).
We have used 2D proton NMR to characterize the folded
structure of our synthetic hepcidin. Spatial proximities
identified in the NOESY spectrum of hepcidin were used
to deduce the correspondence between our folded hepci-
din and the published structure (Figure 2 and reference
[22]). Homology of folding can be recognised by spectral
shift pattern matching in combination with observed
long-range NOE and it is this dual approach, focussing on
specific residues involved in critical contacts within the
hepcidin molecule fold that we used to confirm the archi-
tecture of our synthetic hepcidin. Consistent with the
homology of S-S linkages, the pattern and dispersion of
chemical shifts of backbone -NH (and cysteine -CaH, 4.9–
5.5 ppm – data not shown) obtained for the synthetic
hepcidin matches the shift and intramolecular 1H-1H dis-
tance fingerprint of the published human hepcidin struc-
ture [22].
The biological activity of the refolded labelled hepcidin
was tested by measuring ferroportin internalisation by
immunofluorescence. In the absence of hepcidin ferro-
portin was predominantly localised on the cell border of
THP-1 cells (Figure 3a). Addition of labelled hepcidin
caused a re-localisation of ferroportin immunoreactivity
to the cytoplasm (Figure 3b) whereas reduced (unfolded)
hepcidin had a less marked effect (Figure 3c).
Hepcidin Measurement by SELDI
Spectra obtained from the sera of 5 breast cancer patients
using Cu2+ loaded IMAC arrays are shown in Figure 4. A
peak with m/z 2791 corresponding to hepcidin-25 can be
seen in most of the spectra. There is little evidence of hep-
cidin-20 or the oxidised form of hepcidin-25 in this set of
sera. The background proteome is variable, however, there
is a region of low background to the right of the hepcidin-
25 peak (m/z 2800–2850) offering a window in which to
introduce an internal standard.
Hepcidin Assay Validation
Labelled hepcidin was titrated into serum (0–400 ng hep-
cidin/ml) without influencing the intensity of the endog-
enous hepcidin SELDI peak (Figure 5). In experiments
adding 0–50 ng hepcidin/ml to serum, the lowest concen-
tration of labelled hepcidin generating a reliable peak was
~10 ng/ml indicating that this would also be the limit of
detection of endogenous hepcidin in serum by this
method (data not shown). A working concentration of
200 ng labelled hepcidin/ml was adopted as this produces
a robust peak similar to the highest endogenous peak
observed. We then added 0–400 ng/ml unlabelled and
200 ng/ml labelled hepcidin to a serum sample devoid of
endogenous hepcidin to test whether the peak height ratio
is representative of the concentration (Figure 6a).
Although the edges of the peaks overlap, when the spectra
of 200 ng/ml labelled and unlabelled hepcidin are super-
imposed neither peak contributes significantly to the peak
height of the other (Figure 6b). Plotting unlabelled hepci-
din concentrations calculated from peak height ratios
against actual concentration (Figure 6c) reveals a strong
correlation (the non-zero intercept is largely due to the
endogenous hepcidin in the sera used and a slight down-
wards curvature is seen at very high hepcidin concentra-
tions). This indicates that the peak height ratio produces a
reliable estimate of hepcidin concentration.
To assess the effect of background proteome and instru-
ment variability we used the peak height ratio method to
determine hepcidin in urine with varying amounts of
irrelevant proteins added and at various laser settings (Fig-
ure 7). Urine with ~200 ng/ml endogenous hepcidin was
spiked with 200 ng/ml labelled hepcidin and increasing
amounts of a serum sample not containing hepcidin. The
absolute height of the endogenous hepcidin peak was
strongly dependent on laser power but not affected by the
addition of serum (Figure 7a). Total ion current (TIC) nor-
malisation overcame the dependence on laser power but
was influenced by addition of serum (Figure 7b). The con-
centration of endogenous hepcidin calculated from the
peak height ratio was not influenced by sample composi-
tion or instrument performance as shown in Figure 7b.
Comparison with non-spiked SELDI data
We analysed 24 serum samples with a range of hepcidin
peak heights with and without spiking with 200 ng/ml
labelled hepcidin. The strong correlation between the
endogenous hepcidin peak heights in the spiked and non-
spiked assays (Figure 8a) re-emphasises that spiking has
little effect on the endogenous hepcidin peak height and
shows that the hepcidin peak in carefully performed
SELDI experiments is reproducible (the two experimentsProteome Science 2008, 6:28 http://www.proteomesci.com/content/6/1/28
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FTICR mass spectra of folded and reduced synthetic hepcidin-25 Figure 1
FTICR mass spectra of folded and reduced synthetic hepcidin-25. We show the 3+ion of unlabelled folded hepcidin 25 
(a), reduced unlabelled hepcidin (b), folded labelled hepcidin (c) and reduced labelled hepcidin (d). Spectra were acquired by 
direct infusion in 0.1% formic acid/50% acetonitrile into a ThermoFinnigan LTQ-FT. Reduced samples were treated with DTT, 
zip-tipped and kept at low pH prior to analysis.
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were conducted 10 months apart). A strong correlation (r2
= 0.975) between the endogenous peak height and the
hepcidin concentration calculated from the peak height
ratio is shown in Figure 8b indicating that the SELDI peak
heights relate to the concentration of hepcidin in serum in
this experiment.
Hepcidin Levels in Breast Cancer Patients
We had previously used IMAC chips to analyse serum
from 140 patients with breast cancer and 53 non-cancer
control subjects (mean ages 61.9 and 60.1 years respec-
tively). On average, the hepcidin peak height was signifi-
cantly higher in the cancer group than the control group
(5.46 ± 2.93 versus 4.54 ± 1.86, mean ± SD, p = 0.0126).
The current re-analysis of 24 of these serum samples (with
endogenous hepcidin concentrations spanning the
observed range) spiked with stable isotope labelled hepci-
din indicates that this increase in peak height likely repre-
sents a genuine ~20% increase in systemic hepcidin
concentration in this patient group. The mean peak height
in the non-cancer controls corresponds to ~50 ng/ml hep-
cidin with a range from greater than 200 ng/ml to below
the limit of detection (~10 ng/ml in this experiment,
although this may be improved by spiking at a lower con-
centration and using a higher laser power).
Analysis of reproducibility
This was estimated by analysing 2 serum samples (A: ~50
ng endogenous hepcidin/ml, B: ~120 ng endogenous hep-
cidin/ml), spiked with 200 ng labelled hepcidin/ml in
quadruplicate over 5 successive days (Figure 9). The mean
intra-assay CVs of the endogenous hepcidin concentra-
tions estimated by the peak height ratio approach were
9% and 8% for samples A and B respectively. The mean
NMR analysis of folded synthetic hepcidin Figure 2
NMR analysis of folded synthetic hepcidin. Section of the 1H-1H NOESY spectrum showing crosspeaks associated with 
the backbone -NH and aromatic groups of hepcidin. Through space correlations of the -NH of several of the Cys residues are 
identified. Some of the 1H proximities prescriptive of the published fold of the human hepcidin molecule are circled.Proteome Science 2008, 6:28 http://www.proteomesci.com/content/6/1/28
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inter-assay CVs across the 5 days were 15% and 7%. The
CVs calculated using peak heights alone were, for sample
A, 17% and 16% (intra and inter) and for sample B 28%
and 26%. After TIC normalisation the CVs were 11% and
7% for sample A and 17% and 15% for sample B.
Discussion
Since the discovery of hepcidin there has been great inter-
est in this master regulator of iron metabolism [1]. For the
last seven years the scientific community has awaited a
robust hepcidin assay. To date the two main approaches
for measuring hepcidin in biological samples have been
ELISA and SELDI. Two ELISA approaches exist, one meas-
uring pro-hepcidin (which has proved controversial
[11,23-25]) and a recently described ELISA for hepcidin
measurement in serum [18]. This latter assay is based
upon competition for antibody binding between endog-
enous hepcidin and added biotinylated hepcidin.
Although further validation is required to ensure that this
assay is solely specific for bioactive hepcidin 25, it likely
represents a promising high throughput approach. In con-
trast SELDI has been widely used to measure urinary and
serum hepcidin [5,9-12]. The advantages of SELDI include
the ability to measure different forms of hepcidin, e.g.
hepcidin 20 and 25, and furthermore the assay can be
conducted under denaturing conditions so that protein-
protein interactions should not interfere. Unfortunately,
due to the lack of good internal standards SELDI based
hepcidin measurements are at best only semi-quantita-
tive. This issue has now been partially resolved by Swin-
kels and co-workers utilising hepcidin 24 as an internal
standard [17]. The use of a stable isotope labelled hepci-
din as an internal has so far been limited to LC-ESI-MS
experiments [19]. We have now combined the use of sta-
ble isotope labelled hepcidin and SELDI-TOF-MS to gen-
erate a technically simple high-throughput quantitative
hepcidin assay.
The use of stable isotope labelled peptides to make mass
spectrometry based proteomic experiments quantitative is
well established and widely used as exemplified by the
SILAC and ICAT methods [26,27]. Stable isotope labelling
introduces additional neutrons altering the mass of a pep-
tide but does not alter the electronic structure and hence
the binding and ionisation/detection during SELDI
should be unaffected. In this study we apply this approach
to the measurement of hepcidin. We synthesise a stable
isotope labelled hepcidin that is 10 Da heavier than
endogenous hepcidin. After checking that the synthetic
hepcidin adopts the correct folded structure using FTICR-
MS, NMR and a bio-assay we validate its use as an internal
standard in SELDI experiments and demonstrate the mer-
its of this approach.
The isotopic envelope of the labelled hepcidin does not
overlap with the isotopic envelope of endogenous hepci-
din and even when using the PBSIIc instrument (a sensi-
tive but low resolution mass spectrometer) there is
minimal overlap between the labelled and endogenous
hepcidin peaks. A small amount of overlap with oxidised
endogenous hepcidin does occur and it is therefore
important to minimise sample (and standard) oxidation.
Oxidation of hepcidin has previously been reported as an
ex vivo artefact [17] and is usually minimal in serum but
does occur in urine over time. Hepcidin oxidation can
largely be prevented by rapid sample processing and
avoiding long periods at room temperature. It should be
noted that, regardless of internal standards, total hepcidin
The effect of stable isotope labelled hepcidin on ferroportin immunolocalisation Figure 3
The effect of stable isotope labelled hepcidin on ferroportin immunolocalisation. Ferroportin immunoreactivity on 
THP-1 cells incubated without labelled hepcidin (a), with folded labelled hepcidin (b) and reduced labelled hepcidin (c). Arrows 
denote areas of positivity.
a                               b                                cProteome Science 2008, 6:28 http://www.proteomesci.com/content/6/1/28
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SELDI spectra of human sera Figure 4
SELDI spectra of human sera. IMAC spectra of 5 serum samples with increasing hepcidin peak heights (top to bottom). 
Green shading denotes a region of spectrum close to the endogenous hepcidin peak suitable for design and inclusion of an 
internal standard.Proteome Science 2008, 6:28 http://www.proteomesci.com/content/6/1/28
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levels cannot be determined in oxidised samples from the
sum of the non-oxidised and oxidised peak heights as the
relative ionisation efficiencies are unknown. Additional
precautions when using SELDI with or without spiking are
to collect and average a large number of laser shots and to
use appropriate laser power to ensure substantial, but not
saturating peak intensities. The experiments presented
here show that, when these conditions are met, the peak
height ratio approach offers a quantitative assay for hepci-
din.
We find a good correlation between SELDI peak heights
and the peak height ratio method adding weight to previ-
ous reports inferring changes in hepcidin concentration
from SELDI peak heights [5,9-12]. In addition we now
report a small but significant increase in systemic hepci-
Titration of labelled hepcidin into serum samples Figure 5
Titration of labelled hepcidin into serum samples. Labelled hepcidin was spiked into sera with low (a), medium (b) and 
high (c) levels of endogenous hepcidin (estimated from SELDI spectra). The endogenous hepcidin produces a peak at m/z 2791 
and the labelled hepcidin a peak at m/z 2801. Labelled hepcidin concentrations are: bold red line: 0 ng/ml, dashed blue line: 100 
ng/ml, dashed green line (200 ng/ml), dashed black line: 400 ng/ml.Proteome Science 2008, 6:28 http://www.proteomesci.com/content/6/1/28
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din in breast cancer patients. We find the average hepcidin
concentration in healthy females to be ~50 ng/ml similar
to the 65 ng/ml that Ganz et al determined by ELISA [18].
The use of the stable isotope labelled hepcidin alone does
not increase the sensitivity or precision of SELDI measure-
ments as demonstrated by intra- and inter-assay CVs sim-
ilar to those using TIC normalised peak height alone. The
major advance is that the labelled hepcidin approach
should allow hepcidin levels to be measured in absolute
concentration units independent of instrument/operator
or background proteome variations. In the absence of
labelled hepcidin spiking, conversion of peak heights into
concentrations requires external calibration using a series
of dilutions of hepcidin. This is not ideal as at high dilu-
tions hepcidin either adheres to plasticware, precipitates
SELDI analysis of hepcidin mixes Figure 6
SELDI analysis of hepcidin mixes. a) spectra of serum with 200 ng/ml labelled hepcidin (L) added in addition to 67–400 ng/
ml unlabelled hepcidin (U) as indicated in the grey boxes. b) spectra of labelled (dotted line) and unlabelled (solid line) hepcidin 
at 200 ng/ml in serum and the sum of the 2 spectra (bold line). c) shows the concentration of unlabelled hepcidin calculated 
from the peak height ratio plotted against the actual concentration in the experiment of Figure 6a and two independent repli-
cates in different sera. The trend line represents a least-squares linear regression (r2 = 0.990).
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Hepcidin analysis in urine under different conditions Figure 7
Hepcidin analysis in urine under different conditions. A urine sample was diluted to 20 μg protein/ml and spiked with 
200 ng/ml labelled hepcidin and 0–32% (v/v) human serum devoid of hepcidin (as estimated from SELDI spectra – see the top 
spectrum in Figure 4). Panel a: endogenous hepcidin peak intensity with/without TIC-normalisation plotted against laser power. 
Filled symbols denote mean (± SEM) non-normalised intensity of all 8 samples at each laser setting (not [serum] dependent). 
Open symbols denote mean (± SEM) TIC-normalised intensity of the 4 samples with 0–32% serum added (the TIC normalised 
is [serum] dependent). Panel b plots the TIC-normalised hepcidin intensity and the concentration calculated from the peak 
ratio over a range of serum concentrations (constant laser power).
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Comparison of hepcidin concentration and SELDI peak height Figure 8
Comparison of hepcidin concentration and SELDI peak height. Two independent SELDI analyses of 24 serum samples 
are shown in Figure 8a. SELDI was performed in triplicate following spiking with 200 ng/ml labelled hepcidin and compared with 
SELDI without spiking (performed in duplicate). Symbols denote the means of experimental replicates, the least-squares linear 
regression (R2 = 0.827) is shown as a solid line and the ideal 1:1 relationship as a dashed line. Figure 8b shows the relationship 
between endogenous hepcidin peak height and concentration determined from the peak height ratio in the spiked experiment. 
Symbols denote mean (± SEM) of experimental triplicates and the trend line least-squares linear regression (R2 = 0.975).
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or aggregates and mass spectrometry detection becomes
variable (Ward et al, unpublished observations). This
problem can be largely overcome by storing a concen-
trated labelled hepcidin solution in aliquots at -80°C,
doing a single dilution in 8 M urea/1% CHAPS and spik-
ing directly into samples. Addition of stable isotope
labelled hepcidin to serum prior to sample work-up for
mass spectrometry will enable multi-step hepcidin enrich-
ment (followed by SELDI or MALDI) which will ulti-
mately improve the sensitivity of the assay over the single
step retentate chromatography of SELDI.
We conclude that by spiking stable isotope labelled hepci-
din into clinical samples it is possible to turn high-
throughput SELDI analyses into robust hepcidin assays.
SELDI measurements without spiking reflect hepcidin
concentrations but addition of stable isotope labelled
hepcidin improves confidence in the data and provides
absolute concentrations facilitating inter-study and inter-
laboratory hepcidin comparisons.
Abbreviations
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